Increasing rates of ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in Canadian Hospitals: 17 years of the CANWARD study, 2007–23
ESBL E. coli and K. pneumoniae have increased in prevalence, with evolving resistance patterns. While MDR in E. coli has declined, resistance to key antimicrobials, including sulphonamides, fluoroquinolones and first-generation β-lactam/β-lactamase inhibitors remains high. Resistance rates varied significantly by region of Canada and by inpatient status, sex and specimen type.
Authors
- Laura F. Mataseje (ORCID: https://orcid.org/0000-0002-8014-1107)
- Heather J. Adam (ORCID: https://orcid.org/0000-0002-5646-6454)
- Melanie R. Baxter
- Philippe Lagacé‐Wiens (ORCID: https://orcid.org/0000-0002-5826-2869)
- Andrew Denisuik
- James A. Karlowsky (ORCID: https://orcid.org/0000-0002-1939-464X)
- Andrew Walkty (ORCID: https://orcid.org/0000-0003-2880-2104)
- Melissa McCracken
- George G. Zhanel (ORCID: https://orcid.org/0000-0002-3238-0082)
Institutions
- Manitoba Health (CA)
- Public Health Agency of Canada (CA)
- Shared Health (CA)
- University of Manitoba (CA)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-06-28
- DOI
- https://doi.org/10.1093/jac/dkaf220
- Citations
- 1
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.59
Funders
- Pfizer
- Sunovion
- Merck KGaA
- University of Manitoba
- Shionogi
- Sandoz Canada